SCHEMBL5879137

SCHEMBL5879137

CN1C(=O)C=C(c2c[nH]c3ccc(OCc4ccccc4)cc23)C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 3/20 0.49
TRPM8 Q7Z2W7 3/20 0.49
KDM4E B2RXH2 1/20 0.49
MAPT P10636 1/20 0.49
LTA4H P09960 2/20 0.48
PLA2G2A P14555 2/20 0.48
ACHE P22303 1/20 0.48
SLC6A4 P31645 1/20 0.47
POLB P06746 1/20 0.47
MEN1 O00255 1/20 0.47
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
KMT2A Q03164 1/20 0.47
ATP4A P20648 2/20 0.46
ATP4B P51164 2/20 0.46
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
MDH2 P40926 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MAOB P27338 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7809511 0.82 PDE4B (0.50) HTR1DKDM4EMAPTSLC6A4MEN1
SCHEMBL5339384 0.80 HTR1D (0.48) HTR1DTRPM8KDM4EMAPTLTA4H
SCHEMBL5879305 0.79 TRPM8 (0.52) HTR1DTRPM8KDM4EMAPTLTA4H
SCHEMBL7814978 0.78 MAOA (0.58) HTR1DTRPM8KDM4EMAPTLTA4H
SCHEMBL5879168 0.76 SIRT2 (0.63) KDM4EMAPTSLC6A4POLBMEN1
SCHEMBL18392212 0.76 TRPM8 (0.53) HTR1DTRPM8KDM4EMAPTLTA4H
SCHEMBL7815290 0.76 PRKCB (0.60) HTR1DTRPM8KDM4EMAPTLTA4H
SCHEMBL2937196 0.74 CAMK2D (0.49) SLC6A4CYP1A2
SCHEMBL5337023 0.74 MAOA (0.52) HTR1DTRPM8KDM4EMAPTLTA4H
Tert-Butyl Formate SCHEMBL27613248 0.73 ACHE (0.43) HTR1DTRPM8KDM4EMAPTLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 HTR1D 1520/4885TRPM8 4764/4885KDM4E 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.